Results 191 to 200 of about 20,129 (301)

Novel use of telitacicept in primary immune thrombocytopenia: a case report. [PDF]

open access: yesBMC Pediatr
Wang Y   +6 more
europepmc   +1 more source

Integrative Multi‐Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance

open access: yesThe FASEB Journal, Volume 40, Issue 12, 30 June 2026.
Integrated transcriptomic, single‐cell, pseudotime, cell–cell communication, human tissue, and in vivo analyses define a dynamic four‐gene axis across the MASLD continuum. Progressive CYP2C19 downregulation and AKR1B10, COL1A2, and SPP1 upregulation link metabolic dysfunction to disease progression, while AKR1B10 knockdown or CYP2C19 overexpression ...
Kejun Liu   +5 more
wiley   +1 more source

Small Extracellular Vesicles from Neural Cells: Physiological and Pathological Roles, and Potential in Neurodegenerative Therapy

open access: yesAdvanced Healthcare Materials, Volume 15, Issue 21, 5 June 2026.
Neural cell–derived small extracellular vesicles (sEVs) are emerging as pivotal mediators in neurodegenerative diseases, exerting both pathogenic and therapeutic functions. This review synthesizes current evidence on how sEVs from distinct neural cell types regulate neurodegeneration, neuroprotection, biomarker discovery, and targeted drug delivery ...
Muhammad Waqas Salim   +4 more
wiley   +1 more source

Unlocking the Potential of MXene‐Based Electrochemical Biosensors: A Review of Biofunctionalization Strategies and Biosensing Principles

open access: yesAdvanced Materials Technologies, Volume 11, Issue 12, 18 June 2026.
ABSTRACT Electrochemical biosensors enable the accurate and timely detection of clinical biomarkers, improving healthcare and precision medicine. MXene nanosheets, a class of 2D transition metal carbides, nitrides, and carbonitrides, are promising materials for developing next‐generation electrochemical biosensors due to their unique physicochemical ...
Muhsin Ali   +4 more
wiley   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

open access: yesAdvanced Science, Volume 13, Issue 31, 4 June 2026.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy